Key events, in time order
FDA approves Moderna's first mRNA flu vaccine for adults 50+, with supply expected in select retailers in coming weeks.
2026年全年营收增长指引维持在最高10%，预计全年美国与国际市场收入占比约50/50，第三季度营收约占下半年营收的55%。
Q2 revenue of $145M beat estimates, EPS loss of $1.97, but COVID vaccine sales weak
mRNA-1403 missed early success bar, impacting pipeline prospects
Q2 revenue $145M misses, GAAP EPS -$1.97, norovirus vaccine disappoints
None yet
None yet
Moderna experienced a significant price surge driven by positive news, leading to a substantial increase in mentions and upgrades. The stock is seen as a potential double from its current position.
Main discussion
Different voices
🏆 TOP 10 WEEKLY UPGRADES: $MRNA $MRK $AAPL $NBIS $PYPL $OKTA $SNOW $PANW $RBRK $SNAP https://t.co/Fpoomzyjjy
The Moderna $MRNA cashtag increased in mentions on X by 52,430%😳 On Tuesday the 18th, $MRNA was only used 39 times On Wednesday the 19th, mentions spiked up to 20,487 https://t.co/xGHUJ9mBaL
$MRNA Huge move off that cancer news. Short Squeeze there Now watch for a offering, and see how it reacts. https://schrts.co/VSvxvygT
This week, Moderna, $MRNA, spiked more than 150%. Check out Unusual Whales FDA tool to not miss any updates. See more: https://unusualwhales.com/fda-calendar https://t.co/hDNAPCfe8P
HERE ARE THE TOP 15 PERFORMERS OF 2026 1. $SNDK +572% 2. $AEHR +404% 3. $MRNA +392% 4. $TWST +359% 5. $AXTI +333% 6. $AAOI +258% 7. $DELL +251% 8. $MU +239% 9. $MRVL +179% 10. $PENG +169% 11. $NBIS +162% 12. $INTC +144% 13. $DOCN +140% 14. $LITE +135% 15. $BE +132% https://t.co/y
Zoom out on $MRNA This stock could easily double again https://t.co/Ut177SWCO9
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice
Moderna makes mRNA vaccines and therapies, like a biological software company that programs cells to fight diseases—best known for its COVID-19 shot.
Revenue fell from USD 6.85B in 2023 to USD 1.94B in 2025, with gross margins shrinking from 55% to negative—COVID vaccine sales collapsed, and no new product has replaced them.
Its mRNA platform is protected by patents and manufacturing know-how, but rivals like Pfizer and BioNTech have matched the technology, and demand for its only commercial product has evaporated.
